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Heart failure (HF)  is a disease affecting millions of people worldwide.  Currently 
with treatment options that do not address the underlying loss of myocardial cells, doctors 
and researchers have been relentlessly trying to find alternative treatments.  With the 
advancement in stem cell biology, one of the emerging therapies for CHF is cellular 
cardiomyoplasty.  The usual response to cardiac injury is replacement of the dead tissue 
with fibrotic scar.  Cellular cardiomyoplasty theorizes that introducing stem cells to the 
injured region leads to cardiac regeneration and improvement in function.  Embryonic 
stem cells (ESCs) are one source of progenitor cells for cellular cardiomyoplasty because 
of their potency and availability.  Nevertheless, the consequences of ESC application are 
unknown, and previous studies have suggested that other progenitor cells may be 
arrhythmogenic.  Therefore, we studied the electrophysiological implications of ESC-
mediated therapy by evaluating the effects ESCs have on neonatal rat ventricular 
myocytes (NRVMs).   
To mimic expected in vivo engraftment rates, 5% mouse ESCs were co-cultured 
with NRVMs.  Field potential duration (FPD), interspike interval (ISI) and conduction 
velocity (CV) were measured using a multi-electrode array system (MEA).  Comparing 
cultures without and with 5% ESCs at 4 days, the mean bipolar FPD of NRVMs 
increased from 26.3 ± 2.2 ms (n=10) to 44.3 ± 6.2 ms (n=9; p < 0.05), the ISI increased 
from 358.3 ± 62.8 ms (n=10) to 947.8 ± 214.6 ms (n=7; p < 0.01), and CV decreased 
from 14.2 ± 1.3 cm/s (n=8) to 4.6 ± 1.2 cm/s (n=5; p < 0.01).  These initial findings led to 
further evaluation of whether ESCs were having direct or paracrine effects on NRVMs.  
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Media conditioned by 3x106 ESCs for 24 h was diluted 1:1 with fresh media (ESC CM) 
and then introduced to NRVM cultures on the day of plating.  CM was changed daily and 
altered mean FPD, ISI, and CV to 46.1 ± 7.8 ms, ISI to 682.0 ± 128.5 ms, and 4.2 ± 0.4 
cm/s (n=8; p < 0.01 for each measure), respectively at 4 days as compared to media 
treated similarly but with exposure to ESCs. 
  Cardiac sodium (Na+) channel and connexin43 (Cx43) expression were studied as 
possible explanations for the observed decrease in CV in the presence of ESCs.  Western 
blots revealed an increase in phosphorylated Cx43/unphosphorylated Cx43 ratio by 96% 
in the 5% mouse ESCs and 53% ESC CM as compared to controls (n=8; p < 0.01 for 
each).  Also, cardiac Na+ channel expression was significantly decreased to 64.9 ± 6.0% 
(n=8) and 73.8 ± 13.8 % (n=7) of the control for ESCs and ESC CM respectively.  RT-
PCR revealed a similar reduction in cardiac Na+ channels.  Using single cell patch 
clamping techniques, a 38% reduction in cardiac Na+ current was measured.  Also, there 
was a significant decrease in peak Na+ current in ESC CM-treated cardiomyocytes.  In 
addition cardiac simulations were conducted based on experimental Na+ current and 
Cx43 changes.  These simulations revealed a similar decrease in CV. 
In summary, the presence of ESC altered the electrical properties of native heart 
tissue, prolonging CV and APD.  These effects were mediated by soluble factors secreted 
by ESCs and resulted, in part, from reduced Na+ channel and Cx43 levels.  These effects 







1.1 The Epidemic of Heart Disease  
 Today, even with the advent of modern therapies, heart disease still remains a leading 
cause of death worldwide.  According to the Center for Disease Control and Prevention, almost 
23.5 million Americans suffer from heart disease in some form, leading to over 700,000 deaths a 
year and making it the number one killer of both men and women in America.2  As heart disease 
patients, many Americans suffer from a heart attack each year and often develop a condition 
called heart failure (HF).    
 Ironically, while modern therapies have prolonged the life of cardiac patients, these 
therapies have also led to more cases of end stage HF.3  Each year approximately a quarter 
million people die from HF.4  The disease is responsible for over 11 million doctors’ visits and 
3.5 million hospitalizations yearly.5  Unfortunately, in the past 25 years, this is the only category 
of heart disease that has increased in terms of prevalence, hospitalization rate, and cost.6  In fact, 
the number of deaths from heart failure has increased 6-fold in the past four decades and is the 
leading cause of hospitalization in seniors over 65 years old.7  Annually, it is estimated that $25-
40 billion are spent for the care of heart failure patients.5  This makes the cost of hospitalization 
for heart failure twice as much as that for all forms of cancer combined.5  All these statistics 
make it clear that HF as a disease is widespread. 
 HF occurs most commonly when the heart’s ability to pump blood through the body is 
limited.  A failing heart’s inability to  pump decreases blood flow out of the heart, which causes 
venous return to back up and manifest as tissue congestion.8  HF may have deleterious effects on 
the renal, respiratory and hepatic organ systems.    Patients suffering from HF are at a risk for 
heart rhythm disturbances (arrhythmias), and approximately 50% of all deaths related to HF 
result from arrhythmias.9  
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1.2 Current Treatments and Limitations 
While lifestyle changes are used for primary or secondary prophylaxis, most patients with 
HF are dependent on using medications.  Useful medications include diuretics, inotropes, 
vasodilators, and beta blockers.  Despite treatments with these drugs, almost all HF patients will 
experience at least one acute episode that requires hospitalized treatment.  Studies have shown 
that twenty percent of patients hospitalized will experience repeat episodes and that fifty percent 
of those patients end up visiting the hospital again in only six months.10  
One of the major limitations in management of HF is that therapies do not address the 
underlying cause of myocardial dysfunction.  For example, the inability of the heart to pump 
blood efficiently often results in reduced kidney function and increased vascular tone.  Drugs 
like diuretics affect the kidney, while vasodilators affect arterial tone.  These drugs improve the 
effects of heart failure rather than the actual condition of the heart.  These drugs also have 
adverse effects such as electrolyte depletion and hypotension in the case of diuretics7 and 
dizziness in the case of vasodilators.11  
  Studies have shown that the organ systems mentioned above are linked through a 
network of neurohormones.  These hormones, like epinephrine, stimulate the heart to beat faster 
and stronger in order to compensate for the inefficiency of the heart caused by HF.  Doctors 
generally prescribe angiotensin converting enzyme inhibitors (ACE-I) and beta blockers to 
reduce the deleterious effects of increased neurohormones.  Nevertheless,  ACE-I drugs have 
drawbacks: they cannot completely prevent the body from manufacturing angiotensin12 and they 
can lead to hypotension.7    
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Other treatment options like biventricular pacemakers or left ventricular assist devices 
(LVADs) are available to treat HF.13   LVADs can augment or replace myocardial function but 
are generally not considered a permanent solution because of the limitations of power supply, 
increased risk of infection, and increased risk of thrombosis.  In addition, implantation is 
expensive and complicated.  Cardiac transplant is possible but is limited by the number of 
available organs and a 20% 1-year mortality rate.14  
Because of these shortcomings, new methods of treatment are needed.  Alternative drug 
therapies, permanent artificial hearts, and xenotransplantation are currently being researched.  
Another promising therapy is cellular cardiomyoplasty. 
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1.3 Cellular Cardiomyoplasty- A Promising Treatment Option  
An alternative approach to mechanically assisting or transplanting a damaged, 
dysfunctional heart is to generate ‘‘new’’ functional myocardium.  These strategies include 
induction of transdifferentiated adult cells to replace dead myocardium, attraction of endogenous 
progenitor cells, and addition of exogenous progenitor cells.  These approaches have been 
collectively termed cellular cardiomyoplasty.  Often these techniques are assisted by addition of 
factors designed to encourage cardiac cell growth and differentiation. 
The effects of various growth factors on cardiomyocyte proliferation have been studied 
extensively.  Factors such as basic fibroblast growth factor (bFGF),15 insulin-like growth factor 
(IGF-I, II),17  transforming growth factor beta-1 (TGFβ-1)16  and platelet-derived growth factor 
(PDGF) 17  have been associated with cardiomyocyte proliferation.  Cardiomyocyte mitogenic 
factors have also been under investigation with the hope of converting post-mitotic stage 
cardiomyocytes into proliferating cells.20, 21  While research in mitogenic factors is promising, it 
still has not lead to the conversion of terminally differentiated, post-mitotic, myocardial cells into 
proliferating, regenerative cells. 
A possible alternative solution would be converting non-contractile tissue into contractile 
myocardium through a process known as transdifferentiation.  Murry et al.22  were able to inject 
a virus carrying the myoD gene into rat myocardial scar tissue and demonstrated the subsequent 
production of contractile proteins.  Nevertheless, there is no evidence that these transfected cells 
can form contracting myocytes, and the transfection rate was reported to be as low as 14%.22  
Another overriding risk is the tumor potential of these vectors which may limit their clinical 
application. 
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Potentially salvaging the remaining peri-infarct zone is another area of intense research 
interest.  The non-contractile scar tissue is usually surrounded by an area of hibernating 
myocardium and being able to restore blood flow to this region may contribute to helping 
systolic function.  Angiogenic growth factors, such as vascular endothelial growth factor (VEGF) 
and bFGF, have been shown to induce the development of collaterals and increase capillary 
density in ischemic canine myocardium.23  An alternative approach to the use of angiogenic 
factors in restoring regional blood flow is to use transmyocardial revascularization, which uses 
laser- or needle-created channels to induce an inflammatory response that leads to the subsequent 
increase in regional blood flow, probably by stimulating angiogenesis.  Both of these approaches 
are aimed at salvaging any viable, functional myocardium.  It is still not known if these 
approaches produce a clinically significant increase in myocardial function. 
Another area that is being researched is the application of cells that might assist the 
myocardium in generating a contractile force.  In vitro animal studies have demonstrated that 
transplanted cardiomyocytes within a normal or infarcted myocardium remain viable for months 
and have the ability to proliferate and differentiate in situ.18  Other studies have shown the 
presence of intercalated disks and connexin 43 (Cx43), a gap junction maker required for cell-to-
cell electrical coupling, within grafted tissue.25, 26  The graft has shown spontaneous contraction 
with fetal cells or after electrical stimulation when implanted with myoblasts.19  These results are 






1.4  Possible Sources for Cell Therapy 
Several distinct cell types have been used in experimental and pilot trials.   The question 
of which cells are best suited for cardiac regeneration and vascularization has not been answered 
yet, however.  Researchers are looking at neonatal cardiac myocytes, skeletal myoblasts, 
mesenchymal stem cells (MSCs), and embryonic stem cells (ESCs), among others.    
 Cardiomyocyte transplantation is a promising approach for treating HF.  After 
transplantation of embryonic rat ventricular myocytes, studies have reported a trend for increased 
vascularization in an infarcted model with survival of transplanted cells lasting up to 53 days.28  
Transplanting ventricular myocytes into dilated cardiomyopathic hamsters improved ex-vivo 
contractile performance one month after transplantation.29  An investigation by Reinecke et al. 
revealed that neonatal cells expressed the cadherens junction proteins N-cadherin and Cx43, 
indicating potential integration into host tissue.25  Most long term follow-up investigations in 
infarct models reported that integration of engrafted cells appeared to be hindered by scar tissue, 
thus separating the transplant from the host.20  In addition, the availability of such a cell source 
would be limited, if available at all, when used in a clinical application and an appropriate 
immunosuppressive regime would have to be designed.20   
Skeletal myoblasts were investigated because, unlike fetal cells, their use does not 
involve issues like ethics, availability, and immunogenicity.  Also, they are resistant to ischemia, 
the cause of most myocardial injury.  Research on rabbit myocardium demonstrated that 
transplanted autologous skeletal myoblasts improved myocardial performance after 6 weeks.21  
Data from pressure-volume loops indicated that engrafted myoblasts improved global systolic 
function.22  N-cadherin and Cx43, which were expressed in myoblast cultures, were down-
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regulated after implantation, however.33  This study suggests that problems could arise during the 
integration of the graft with the surrounding host tissue. 
Increasing evidence suggests that progenitor cells of the adult organisms have a capacity 
to give rise to several lineages and may be suitable for regenerative medicine.23  These adult cells 
are present in most organs and act as a reserve for replenishing cells that die.  Depending on their 
tendency to adhere to tissue culture plates and their surface markers, adult progenitor cells from 
the bone marrow can be categorized into hematopoietic stem cells (HSCs), endothelial 
progenitor cells, MSCs, or side-population cells.24  For example, multipotent adult progenitor 
cells have been isolated from bone marrow and can differentiate into visceral mesoderm, 
neuroectoderm, and endoderm in vitro.36  
While research is being conducted using all these cell types, currently the most promising 
results come from MSCs.  An innovative study published in Nature showed the potential of adult 
bone marrow cells to improve injured myocardium.37  Cells obtained from transgenic male mice 
were injected into the healthy myocardium adjacent to the infarct site.  In only 9 days, a band of 
myocardium was observed in the treated mice as compared to the control mice.37  In contrast, 
other studies have shown no evidence of MSC-derived cells transdifferentiating into 
cardiomyocytes after transplantation.38    
ESCs are the most primitive cells and have the ability to develop into all of the unique 
cell types that make up the human body.25  Derived from the inner mass of the blastocyst, these 
cells may be harder to isolate compared to their adult counterparts but are potentially more 
beneficial because of their totipotency and ability to proliferate without differentiating.  The later 
property facilitates cellular expansion and addresses the need for large cell numbers required in 
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therapeutic uses.  ESCs are currently the only cell source that can provide ex-vivo an unlimited 
number of cardiac cells for transplantation.  In theory, they can be extensively characterized and 
genetically engineered to promote desirable characteristics such as resistance to ischemia or 
improved contractile function to cater to specific applications.26  Researchers are looking at ESC 
derived cells as gene therapy vehicles aimed at modifying the local myocardial environment by 




1.5 Potential of ESCs as a Cell Source for Cardiac Regeneration 
Research has established that murine ESC (mESCs) can give rise to cardiomyocytes both 
in vitro and in vivo.27,28  Klug et al.27 transplanted mESCs-derived cardiomyocytes into the left 
ventricular wall of mice and found that after transplantation, the donor cells displayed 
cardiomyocyte phenotype. These implanted cells formed stable intracardiac grafts and displayed 
gap junctions.  The selected cardiomyocyte cultures were more than 99% pure and highly 
differentiated.  The genetically selected cardiomyocytes formed stable grafts in adult mouse 
hearts for 7 weeks after implantation.  This study demonstrated the potential of grafts from ESC-
derived cardiomyocytes to survive in normal tissue with adequate vascularizaton.27     
In one study, green fluorescent protein (GFP) expressing, cultured ESCs were injected 
into an infarcted rat heart.  Within six weeks, there was significant improvement in cardiac 
function as compared to the controls.29  Immunostaining against GFP, cardiac sarcomeric alpha-
actin, alpha-myosin heavy chain, or troponin I, experiments confirmed the survival and 
differentiation of engrafted cells.  The shape and size of the transplanted GFP-positive cells were 
similar to the host cardiomyocytes.  These studies indicate that transplanted ESCs survived and 
differentiated in injured myocardium and improved cardiac function.  Similar differentiation 
patterns have also been seen in the tissue culture studies using human ESCs (hESCs).30   
Other studies have looked at the longer-term benefits of ESC transplantation on cardiac 
function.45  GFP expressing mESCs were implanted into the border region of the infarct area.  
After 32 weeks, researchers noticed increased survival in the MI rats with ESC transplantation.  
Hemodynamic and echocardiographic data showed significant improvement of cardiac function.  
GFP-positive tissue was indentified in the infarcted region and showed the presence of several 
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cardiac proteins.  These data suggest that ESC grafts exhibit long-term survival capabilities and 
may contribute to the long-term improvements in heart function.    
The percentage of ESCs that differentiate into cardiac myocytes is low (typically only 1% 
of a differentiating culture).31  Due to the large number of ESCs needed for clinical applications, 
it is important to develop a streamlined process where a large number of cells can be 
differentiated quickly in vitro, especially in terms of developing pure cultures of myocytes for 
cardiac therapies.  Studies are being done to investigate ways to increase the number of cardiac 
progenitor cells from ESCs using approaches like retinoic acid, inhibition of bone morphogenic 
protein (BMP) signaling, and modulating Wnt signaling.32, 33   
Some research groups have looked into implanting undifferentiated ESCs into the 
myocardium.  While studies have shown undifferentiated ESCs have signaling mechanisms that 
cause cardiomyocyte differentiation and lead to improved cardiac function,34  these cells also 
have a high risk for developing into teratomas.35  The tendency to form teratomas is a major 
limitation for the use of ESCs for human cardiac repair.  Another limitation is immune rejection.  
Possible options to overcome this problem include stem cell banks to reduce donor-recipient 
differences, immunosuppressive therapy, and creation of “universal” donor cells by genetic 
manipulation.36   
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1.6 Cell Replacement Therapies and Arrhythmic Risk 
The previous sections discussed the variety of cell sources that are currently being 
investigated as replacement sources.  Unfortunately, no consensus has been reached on what is 
the optimal cell source.   This is partially because of the possibility of arrhythmic risk 
demonstrated by experimental and clinical trials.  Arrhythmias may offset some of the benefits 
associated with cell replacement.  Therefore, many studies are looking at potential risk 
associated with cell therapy options. 
Over the past 2 years, a number of early-phase clinical studies have started addressing the 
question of safety in cardiac cell transplantation.  These studies have predominantly used skeletal 
myoblasts and bone-marrow-derived stem cells.  In 2001, autologous skeletal myoblasts were 
expanded ex-vivo and injected into the post infarcted scar.  After 5 months, there was improved 
contraction in the native myocardium.37  These results suggested that the improved function of 
the scarred area was probably related to the engrafted myoblasts.  While these results seemed 
promising at the time, a follow up study in 2003 found an occurrence of arrhythmias in many 
patients in this clinical trial.38  The arrhythmias could have been due to differences in the 
expression channels of skeletal myoblasts and cardiomyocytes.  Other potential causes include 
an inflammatory response to the exogenously applied cells.39  An alternative theory is that 
reentry pathways could be created by cell-independent, injection-related disorganization in the 
border area of the infarcted region.53   
 In 2005, Abraham et al.55 published results that offered new information regarding 
arrhythmic risk associated with skeletal myoblast transplantation.  Using an optical mapping 
system, the group studied the electrophysiological effects of skeletal myoblasts on a 2-
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dimensional (2D) cardiomyocyte culture.  They demonstrated that skeletal myoblasts did not 
electrically couple well with the neighboring cardiomyocytes.  The skeletal myoblasts increased 
the occurrence of reentrant circuits in these 2D cultures.  In their studies, they also demonstrated 
that only by induced expression of Cx43 they were able to reduce the arrhythmic risk.55    
These results suggest the need for further investigation into the electrical effects of cell 
replacement therapies.  The Abraham et al.55 study suggests that skeletal myoblasts are unable to 
fully integrate into the surrounding myocyte culture and develop contractile function. The 
alteration in the action potentials in skeletal myoblast/cardiomyocyte co-cultures may be related 
to myoblast secreted paracrine factors.  More research into the effects of the Cx43 expressing 
skeletal myoblasts needs to be conducted.  Given the reduced electrical coupling of skeletal 
myoblasts, embryonic stem cell derived cardiomyocytes may be the most likely cell source for 
cardiac regeneration.45   
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1.7 Mechanisms of Arrhythmias 
Ventricular arrhythmias are commonly seen in people suffering from HF.  Three 
fundamental mechanisms exist for arrhythmias: triggered activity, automaticity, and reentry.  
Triggered activity occurs when an action potential (AP) incites a subsequent premature beat 
(Figure 1-1).40  Automaticity refers to the ability of cardiac cells to spontaneously and 
repetitively depolarize in the absence of external stimulation (Figure 1-2).41  Reentry is 
continuous electrical activity facilitated by slow conduction (Figure 1-3).40  These mechanisms 
underlie sudden deaths resulting from heart failure. 
Afterdepolarizations and Triggered Activity 
Triggered activity arising from either early afterdepolarizations (EADs) or delayed 
afterdepolarizations (DADs) is one of the mechanisms that initiates arrhythmia.  Triggered 
activity is caused by oscillations in the membrane potential that follow the upstroke of an AP.  
EADs take place during repolarization of the membrane potential, while DADs occur after 
completion of repolarization (Figure 1-1).  When these oscillations are large enough to hit 
threshold, they invoke a series of premature APs.42  DADs are facilitated by tachycardia, 






Another mechanism of initiation of ventricular arrhythmias is automaticity.  Automaticity 
occurs from a gradually decreasing membrane potential, which creates an AP upon reaching 
threshold (Figure 1-2).  When automaticity arises from cells with normal negative diastolic 
potential, it is called “normal automaticity,” whereas “abnormal automaticity” arises from 




Figure 1-2 – Automaticity.  In abnormal automaticity, the rate depolarization may be increased or the threshold 
potential (TP) reduced, that is, the level that triggers the rapid phase 0 depolarization is more negative. This 
would result in a tachycardia. (Picture: www.lhsc.on.ca/uwodoc/pages/arrmech.htm)  
 
Figure 1-1 – Triggered Activity. In panels A-D, show voltage oscillations known as early afterdepolarizations 
(EADs) as the AP prolongs.  The EADs can eventually reach threshold and lead to triggered spontaneous APs. 
(Picture: Li Y et al.1 ) 
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The electrophysiologic changes that favor automaticity are a decrease in inward 
rectifying current Ik, an increase in the pacemaker current, or a combination of both.  Studies 
found that the pacemaker current, If, is activated at less negative potentials in failing human 
ventricular cells.43  
Reentry 
Reentry is a mechanism of maintenance for ventricular arrhythmias.42  Reentry takes 
place when an impulse returns to excite previously activated myocardial cells that have already 
been repolarized and are in phase 4, the resting potential state.60  Heart tissue that has been 
depolarized for long periods provides the basis for the development of reentry.  Conditions 
favoring reentrance are slow conduction, short refractory periods, large dispersion of refractory 




Figure 1-3 – Reentry.  A classic form of reentry known as "circus movement reentry”  (A)  A particular piece of 
tissue has two potentially conducting pathways (α & β).  During sinus rhythm, the depolarization wave front 
passes across the tissue, depolarizing both pathways. (B) An event, usually an extrasystole, exposes the presence 
of the two pathways since they may have slightly different conduction velocities and recovery rates. The wave 
front blocks in β but conducts slowly down the α pathway, in this case, because the β pathway was refractory.  
(C) By the time the impulse reaches the distal end of the α pathway, the β pathway has recovered sufficiently 
such that the impulse can conduct retrogradely up the β pathway and back down the α pathway. A reentrant 




 As previously mentioned, slowed conduction is the primary cause for reentry circuits.  
Gap junctions play a pivotal role in the CV and signal propagation of cardiac tissue.44  Gap 
junctions are clusters of closely packed channels, which allow for direct connection of 
cytoplasmic compartments of neighboring cells. They allow the passage of ions and small 
molecules.45  To form a gap junction, each of the two cardiomyocytes contributes a connexin 
hemichannel.  Connexin hemichannel are made by oligomerization of six connexins, which are 
transmembrane protein molecules.  Connexin 43(Cx43) is the most abundant connexin in the 
heart and has been found in most parts of the heart except in cells of the sinoatrial and 
atrioventricular nodes.46  Studies have suggested that Cx43 may be the most important 
determinant of myocardial conduction in ventricular cells like NRVMs.47  Research has also 
shown that Cx43 phosphorylation plays an important functional role in gap junction activity and 
in the membrane assembly.48  
 Connexins are not the only proteins responsible for CV.  In the heart, voltage-gated 
sodium (Na+) channels determine the amplitude and slope of the AP, which is especially 
important when it comes to controlling the impulse CV and in maintaining excitation waves.49  
Dysfunctional Na+ channels have been shown to be responsible for several inherited cardiac 
electrical disorders, such as Long QT and Brugada syndromes, potentially leading to fatal 
arrhythmic events.  A recent study, discussed how minor genetic alterations in Na+  channels that 
lead to a loss of current are enough to cause arrhythmic disorders.67  For example, isolated 
cardiac conduction disorder is characterized by slowed intramyocardial conduction, and results 
in a loss of Na+ current.  This can cause individuals to experience bradycardia and syncope 
resulting from delays in ventricular excitation. 50  
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1.8 The Arrhythmogenic Potential of ESCs 
As scientists are looking at the benefits of cellular transplantation, there is also an 
increased concern for possible downside risks such as the potential arrhythmic risk.  Arrhythmic 
risk is known to be inversely proportional to cardiac function.  Since cell therapy results in 
improved function, one important question is whether cellular cardiomyoplasty will suppress an 
arrhythmic tendency by improving cardiac function or whether will it further add to the electrical 
heterogeneity, thereby enhancing any arrhythmic predisposition. 
Stem cell-derived cardiomyocytes have displayed arrhythmic characteristics in vitro.51  
CMs derived in vitro showed AP heterogeneity, maintained automaticity for long periods and 
had prolonged AP durations.  The prolonged AP durations showed easily inducible triggered 
electrical activity.  These findings have important clinical implications, as automaticity and 
triggered activity are known fundamental mechanisms of arrhythmias.  hESC-derived 
cardiomyocytes also show similar behavior.52   
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1.9 Specific Aims 
Cellular cardiomyoplasty is being considered as a possible therapy for cardiac 
regeneration.  While numerous sources exist, ESCs are one source of progenitor cells for cellular 
cardiomyoplasty because of their potency and availability.  Although potent, the risk factors 
associated with ESC application are unknown.  Previous studies have shown the arrhythmogenic 
potential of in-vitro ESC-derived cardiomyocytes, but studies have not looked at the 
electrophysiological changes in native cardiomyocytes caused by the introduction of ESCs, 
however.   
 There are three main specific aims for the project: 
1.  Do ESCs cause alterations in cardiomyocyte electrophysiology? 
2. What is the underlying ionic basis of any observed changes?  
3. How do ESCs affect these changes in cardiomyocytes? 
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CHAPTER 2 
TOOLS AND METHODS 
 Hodgkin and Huxley were the first to study the electrical activity of a squid axon by 
voltage-clamping and obtained the first intracellular recording of an AP.53  The development of 
the patch clamp, which allows one to study single ion channel changes, provided a better 
understanding of the molecular mechanism of cardiac AP generation.54  Both of these techniques 
were limited because they did not allow assessment of CV and lacked the ability to conduct long-
term measurements, which are essential for studying the efficacy of drug treatments, cell-based 
therapies, and other treatment options.     
2.1 MEA - a Tool for Electrophysiology Measurements 
 The multi-electrode array (MEA) system overcomes these limitations by recording 
simultaneous extracellular potentials from a monolayer of cells deposited on top of its detection 
surface.  The MEA is a glass dish with 60 titanium nitride coated gold electrodes arranged in a 
two-dimensional (8 X 8) configuration on the floor of the dish (Figure 2-1).  The relatively small 
dimensions of the electrodes and precise positioning capabilities support high spatial resolution 
recordings and can be helpful in the analysis of the activity of complex, multi-cellular systems.  
The minimal invasiveness of the MEAs also allows for long term cell recordings.73  Each 
electrode records extracellular electrical signals of aggregated cardiomyocytes called field 
potentials (FP).55  
     Although the FP components are not identical to the intracellular AP, they can provide useful 
information about the effects of various electrophysiological changes on the excitation 




MEA Measurements and Their Significance 
Three fundamental mechanisms exist for arrhythmias: automaticity, reentry and triggered 
activity.  MEA measurements record information about FPD, ISI, and CV.  These measurements 
can be useful in assessing arrhythmic risk because they can provide information regarding the 
underlying mechanisms. 
The FP measured by an MEA can be analyzed in terms of the minimum, maximum, and 
duration (Figure 2-2).  FP duration is the time between the initiation of depolarization and the 
end of repolarization.  Halbach et al. demonstrated that FPs recorded from multi-cellular 
preparations of myocytes contain information about APD and individual transmembrane currents 
(Figure 2-3).1  Thus, characterization of the FP allows researchers to estimate AP changes and 
the contribution of individual current components to the AP non-invasively.1    
 
Figure 2-1- Schematic of the MEA culture dish.  Cells are cultured in a glass MEA dish lined with 60 electrodes 
(black) spaced at 200 µm in an (8x8) arrangement.  Cardiomyocytes (yellow) attach to the bottom of the dish, 
where they generate individual cardiac action potentials (AP).  Each electrode records the cardiac field potential, 
which is the combination of the signals generated by each cell. 
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The ability to estimate AP is important in cardiac research because increases in AP 
duration can lead to triggered activity.  Since MEAs can provide duration information, one can 
compare FP durations of various cultures.  Given that a relationship between AP to FP exists, it 
is possible to study the effects of a cardiomyocyte/ESC co-culture condition on FP duration and 





Figure  2-3 – FP to AP correlation. Simultaneous measurements of FPs and APs recorded from multi-cellular 
preparations of spontaneously active isolated embryonic mouse cardiomyocytes.  Linear relationships between 
the AP rise time and duration and the FP rise time and duration exist. (Picture: Halbach et al.1 )  
 
Figure 2-2 – A representative FP.  A FP waveform recording labeled with FP minimum (FPMin), FP maximum 
(FPMax), and FP duration (FPDur). (Picture: Halbach et al.
1) 
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Interspike interval (ISI), the inverse of the spontaneous beating rate of the in vitro 
cardiomyocyte culture, can also be obtained from MEA recordings. These measurements are 
significant because ISI is a measure of automaticity (Figure 2-4).  
 
While the MEA cultures are too small to assess reentrant arrhythmias directly, they can 
be used to determine the CV, a strong determinant of this type of arrhythmia.  Since MEAs can 
measure signals from multiple electrodes simultaneously, it is possible to measure the CV as an 
excitation wave moves through the culture.  CV is the speed at which the electrical signal travels 
through cell culture (Figure 2-5).  CV provides information about cell-to-cell communication, 
which is reflected by depolarization and repolarization characteristics of the AP.  Information 
about gap junction remodeling can also be obtained from the CV.  Structural changes of gap 
junctions can predispose the myocardium to arrhythmias, and studies have shown that as CV 
decreases, the Cx43 density in cultures also decreases.75  In general, a decreased CV correlates 
with an increased possibility of reentry. 
 
Figure 2-4- ISI Measurement.  FP recording taken over a one second time interval from a single electrode.  




Figure 2-5 – Representative activation map for a culture.  The site of earliest activation is initiated in the upper 
right hand corner and spread through the culture.  The grayscale gradient depicts isochrones of activation.  
Similarly in the human heart, APs are generated in a single area (sinoatrial node) and spread through the atria by 
cell-to-cell contact.  CV can be calculated using activation times and isochrones for direction.   
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2.2 Methods and Techniques 
Embryonic Stem Cell Culture 
For all the experiments conducted, the ESCs were isolated from the mouse ESC R1 cell 
line (ATCC, Manassas, VA).  The R1 ESCs were seeded onto feeder layers grown in T-25 
flasks.  The ESC media consisted of high-glucose Dulbecco's Modified Eagle's Medium (Gibco, 
Carlsbad, CA) supplemented with 15% FBS, 200 mmol/L L-glutamine, 5 X 10-5 mol/L β-
mercaptoethanol, 10 mmol/L non-essential amino acids, 5000 U/mL penicillin/streptomycin, 50 
mg/mL Leukemia Inhibitory Factor.  ESCs were expanded for 48h and then split to prevent 
differentiation.   
When the cells were not used in experiments, they were centrifuged, put in dimethyl 
sulfoxide freezing media (Sigma-Aldrich, St. Louis, MO) and stored for the first 24 h at -70°.  
After 24h, they were transferred into liquid nitrogen.  When needed, these cells were thawed and 
re-suspended in ESC media and grown as normal.  Cell numbers and viability were measured 
using a hemacytometer and trypan blue exclusion test.  In the trypan blue exclusion test, a cell 
suspension is mixed with a dye and then visually examined to determine whether cells take up or 
exclude the dye.  A viable cell will have a clear cytoplasm whereas a nonviable cell will have a 
blue cytoplasm. 
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Neonatal Rat Cardiomyocyte Isolation and Culture 
 Ventricular cardiomyocytes were isolated from 2 to 3 day-old Sprague-Dawley rats 
(Charles River Laboratories, Wilmington, MA) using a isolation kit purchased from Worthington 
Biochemical Corporation (Lakewood, NJ).  Isolations were preformed by the method described 
in Appendix A.  Briefly, the beating hearts of anesthetized Sprague-Dawley rats were surgically 
removed and then immediately placed in a centrifuge tube containing 35 mL sterile calcium- and 
magnesium-free Hanks Balanced Salt Solution (pH 7.4).  The suspension was incubated 
overnight at 4°C with trypsin (50µg/ml).  On the following day, the tissue was treated with a 
trypsin inhibitor for 30 min, followed by collagenase for 45 min both at 37°C.  The tissue was 
titrated and the supernatant was filtered through a cell strainer.  Then, the cells were centrifuged 
at 1000 rpm for 3 min, and the cell pellet was re-suspended in cardiomyocyte media consisting 
of DMEM, 10% Fetal Bovine Serum (FBS), and 200µg/mL penicillin/streptomycin.  After 
measuring cell yield and viability with the trypan blue exclusion test, cells were plated on tissue 
culture dishes for 1.5 h to allow the attachment of non-myocytes.  The non-adherent cells were 
collected and recounted using a hemacytometer.  Cells were plated onto an MEA dish, and the 
cultures were maintained at 37°C in a humidified incubator (95% air/5% CO2).  Unattached cells 
were removed by washing with Phosphate Buffered Saline (PBS) after 24 h.  The medium was 
replaced daily, and all experiments were conducted within a week of cell isolation.  
Neonatal Rat Cardiomyocyte Co-Culture with Embryonic Stem Cells 
 In the control group, consisting of neonatal cardiomyocytes only, cells were plated on an 
MEA at a seeding density of 2 X 106 per MEA.  In the 5% ESC treatment group (5% ESC), 2 X 
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106 cardiomyocytes were co-cultured with 1 X 105 ESCs.  All MEAs were pre-coated with 0.1% 
gelatin to allow for better adhesion.  
Neonatal Rat Cardiomyocyte Co-Culture with ESCs Conditioned Media 
 To create ESC conditioned media (ESC CM), media bathing 2 X 106 ESCs for 24 h was 
removed and mixed with cardiomyocyte media 1:1 to avoid the cell apoptosis that is seen with 
undiluted CM.  For the control and ESC CM groups, 2 X 106 cardiomyocytes were plated onto an 
MEA culture dish.  The media was changed every 24 hours. 
Western Blot Analysis  
 All cultures were washed in ice-cold phosphate-buffered solution at 96 h, harvested in a 
RIPA buffer consisting of 50 mmol/L Tris, 150 mmol/L NaCl, 1% Igepal CA-630 (NP-40) , 
0.5% Na+  deoxycholate, 0.1% SDS, 5 mmol/L EDTA, 1 mmol/L PMSF, 1 µg/mL phosphatase 
inhibitor (Sigma Chemicals)  and 1 µg/mL protease inhibitor (Sigma Chemicals).  The cells were 
then scraped from the dish and the cells’ membranes were disrupted by sonication for 2 min.  
Homogenate protein concentrations were determined by the Lowry protein assay (Bio-Rad, 
Hercules, CA).  Protein (15 µg) was loaded in each well of a pre-casted 10% Tris-Glycine 
polyacrylamide gel (Cambrex Bio Science Rockland, Rockland, ME).  The gel was run at 100 V 
for 1.5 h at room temperature and then blotted onto a nitrocellulose membrane for 1 h at 15 V.  
The membrane was blocked with 5% milk for 1 h and incubated with a rabbit polyclonal anti-
Cx43 antibody 1:2000 dilution (Sigma Chemicals) in 5% BSA at room temperature for 1 h.  The 
blot was further incubated with goat anti-rabbit HRP-conjugated secondary antibody (Sigma 
Chemicals) in 1:2000 dilution in 5% BSA for 1 h at room temperature and visualized using the 
ECL plus chemiluminescence kit (Amersham Biosciences, Piscatway, NJ).  Tubulin or GAPDH 
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expression were used as loading controls and probed sequentially with rabbit monoclonal anti-
Tubulin (Sigma Chemicals) or rabbit monoclonal anti-GAPDH 1:5000 (Sigma Chemicals)  and 
goat anti-rabbit HRP-conjugated 1: 2000 secondary antibody (Santa Cruz Biochemicals, Santa 
Cruz,  CA) in 5% BSA solutions.  Cardiac Na+ channel expression was targeted with rabbit 
monoclonal anti-cardiac Na+ channel antibody (1:1000), which was generously provided by Dr. 
Peter Mohler from the University of Iowa.  Tubulin was used as a loading control for the Na+ 
channel protein studies.  The intensity of the individual bands was quantified using ImageJ (NIH 
software, Bethesda, MD).       
Reverse Transcription Polymerase Chain Reaction 
The expression of the cardiac Na+ channel protein scn5a was confirmed using 
quantitative real-time RT-PCR.  Total RNA from untreated and treated cardiomyocytes was 
isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) with the addition of RNase–free 
DNase I.  Reverse transcription was carried out at 42°C for 30 min with iScript reverse 
transcriptase (Bio-Rad), 1 µg total RNA, and 4 µL of 5x iScript reaction mix following the 
manufacturer’s instructions.  The first strand cDNA was used as template for subsequent PCR 
reactions.  Each PCR reaction contained 12.5 µL of IQ SYBR Green Supermix (Bio-Rad) and 
2.5 µmol/L primer pairs in total 25 µL reaction volume.  The forward primer rtPCRscn5aF (5’ 
GAAGAAGCTGGGCTCCAAGA 3’) recognized a sequence from exon 26.  The reverse primer, 
rtPCRscn5aR (5’ CATCGAAGGCCTGCTTGGTC 3’), was complementary to exon 27 of scn5a 
cDNA.  The reactions gave rise to a 101 bp PCR product.  All amplifications were performed in 
triplicate and consisted of 40 cycles of 30 s at 95°C, 30 s at 60°C, and 30 s at 72°C in a BioRad 
thermocycler iCycler.  PCR products were analyzed by relative standard curve methods.  β-Actin 
was used as a reference for making quantitative comparison.     
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Electrical Activity Recordings 
Extracellular recordings from the cultured neonatal rat cardiomyocytes were performed 
using a MEA data acquisition system (Multi Channel System, Reutlingen, Germany).  The MEA 
was connected to an amplifier system, which included a heat source.  Simultaneous recordings of 
extracellular potential from all electrodes were performed at a sampling frequency of 10 kHz and 
a temperature of 37°C.  Internal channel #15 was used as a reference electrode.  Recordings were 
considered significant when at least 50% of the total electrodes on the MEA recorded 
depolarizations of -10 µV or greater.  As described previously in Halbach et al., the data were 
analyzed off-line with a customized toolbox programmed for MATLAB (Mathworks, Natick, 
MA). 35  FP parameters were averaged for five predefined locations on the array, four in each 
quadrant and one in the center (Figure 2-6).  CV was determined using the activation time and 
the distance between adjacent electrodes.  The direction of signal propagation was taken to be 
normal to the isochrones.  CV was calculated by taking the average velocity in three pre-
specified directions of propagation.  This was done to minimize the error resulting from any 
inhomogeneities in proprogation.  The angle between the lines was set at 45°. CV is path 
independent in MEAs, and is based on the idea of uniform conduction, which may not be the 
case always.   
Comment [SCD1]: This is not at all 
clear. How did you chose the lines?  
What was the angle between the lines?  
How was averaging done?  Why was this 
done if CV is path independent? 
Comment [PK2]: Does this clarify 








Figure 2-7 - CV determination in cultured NRVMs.  The CV is calculated from the paths shown in pink.  This 
map shows the time delays between pacemaker activation and activation at a given location on the MEA.  Blue 
indicates the origin of the spread of excitation (the pacemaker site).  The color gradient corresponds to time 
delays from pacemaker activation.   
 
 
Figure 2-6 – Measurements of FP parameters. A screen shot of one second recordings of the FP from all 
electrodes with five representative electrodes highlighted in red.  These five highlighted electrodes were the five 
most often used for determining the mean FP duration and ISI in a preparation.  If sufficient signal was not 
available at these electrodes, new electrodes were chosen, which maintained the same geographic relationship. 
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Whole-Cell Voltage-Clamp Electrophysiology 
 Whole cell patch clamping was used to determine the effects of changes in Na+ channel protein 
expression on Na+ current.  Cardiomyocytes were plated onto plastic cover slips in 24-well plates on the 
day of isolation.  There were two groups for these experiments: ESC CM and control.    Glass pipettes 
were pulled on a Sutter Model P-97 horizontal puller to create a resistance of 1.5 to 2.5 MΩ.  The glass 
pipettes were filled with a solution of (in mmol/L) CsCl 60, Cesium Aspartate 80, EGTA Na+ 11, HEPES 
10, Na2ATP 5 and pH 7.2 with CsOH.  The bath solution consisted of (in mmol/L) Na 30, N-methyl-D-
glutamate chloride 100, CsCl 5, CaCl2 2, MgCl2 1.2, HEPES 10, Glucose 5 and pH 7.4 with HCl.  Once a 
seal between the cell membrane and the pipette was established, a small amount of suction was applied to 
obtain whole cell current measurements.  The holding potential of the cell was maintained at -100 mV.  
The voltage was stepped from -100 mV to +60 mV to test the presence of voltage-gated Na+ channels.  
Voltage was increased at 10 mV intervals and currents were measured at each interval.  In all recordings, 
80% of the series resistance was compensated, yielding a maximum voltage error of ~1 mV.  Data were 
sampled at 10 kHz and later filtered at 5 kHz for analysis.  Currents were recorded and analyzed with an 
Axopatch 200B amplifier, Axon Digidata 1230A A/D converter and pClamp software (Molecular 
Devices Corporation, Sunnyvale, CA).  
Calculations of the Decreases in CV  
The simulations in this study were based on the Luo-Rudy (LR)56’
57 model, which is a 
theoretical model of the mammalian ventricular AP.  In this model, the AP is constructed from 
the various ionic processes that were derived from experimental data obtained from studies 
performed on guinea pigs.  The LR model was used to correlate in vitro changes in CV to 
changes in Na+ and connexin concentration.   
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The LR model was used in two configurations: 1) a one-dimensional fiber consisting of 
130 cells and 2) a 2D model consisting of 400 x 400 cells.  In the first case, the theoretical fiber 
is composed of serially arranged ventricular cells.  The LR model was used to compute the ionic 
currents and concentration changes, for each cell in the fiber.  The details of the theoretical fiber 
are provided in an earlier publication.58  Briefly, the temporal transmembrane current fluxes of 
the LR model are related to the spatial (axial) current flow by a finite difference approximation 
of the cable equation:58  
                   Equation- 1 
where Iion represents the individual membrane ionic currents, Is is the stimulus current density, a 
is the radius of the fiber, Cm is the membrane capacity, V
t
i is membrane potential at cell i and 
time t, ∆x is the discretization element (in this case equal to the length of 1 cell), RCG is the ratio 
between capacitive and geometrical areas, and Ri is the axial resistance per unit length. Ri is in 
turn composed of myoplasmic resistance (Rmyo) and gap junction resistance (normal Rg = 1.5 
ohm cm2, which corresponds to a conductance of gj = 2.5 microS).  A gj= 2.5 µS results in a CV 
of 56 cm/s, which is typical of propagation along the fibers. A gj = 0.37 µS results in a CV of 
14.3 cm/s (the CV value for the control group), which is typical of transverse propagation.  The 
equation was solved for Vti using the Crank-Nicholson implicit method.  Extracellular resistance 
and flux boundary conditions at the edges were neglected.   
Calculations in the 2D model were made using the LR phase 1 model 56 instead of the LR 
phase 2 model for the sake of simplicity and computational efficiency.57  A more detailed 
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description of the 2D model can be obtained in a previous publication.59  Briefly, 2D tissue can 
be treated as a continuous system in which propagation can be modeled by a partial differential 
equation of the form: 
                                                                           Equation- 2 
where V is the membrane voltage, D is the diffusion current coefficient and Iion is the sum of 
ionic currents.  Equation 2 was solved using a modified version of the Crank-Nicholson implicit 
method.  
These simulations were performed by Dr. Prakash Viswanathan at the University of 
Pittsburgh.  In these studies, the effect of Na+ and connexin modulation on AP conduction was 
studied.  An external stimulus was applied at specific start sites to initiate an AP (Figure 2-11).  
A stimulus was applied to cell 1 in the 1D model and to the middle of the culture at position 
(200,200) in the 2D model.  CV was calculated by dividing the distance between the cells (40 x 
∆x) by the difference between the time that the upstroke velocity reaches a maximum at cell 80 
and cell 40 in the fiber.  A similar method was used in the 2D model for calculating CV. AP 
propagation was assumed to be uniform in all directions.  The connexins were modeled as simple 
resistors between cells.  The resistance of the connexins (Rg) leads to changes in the CV.  The 
gap junction conductance (gj) was chosen such that AP propagation was uniform in all 
directions.  The initial values in the model were chosen to mimic a CV of 15.5 cm/sec, which is 
based on experimental control CV data.  gj was reduced by a fixed percentage to mimic the 
changes in connexin expression observed in experiments (Figure 3-8).  Na+ channel changes 
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were modeled by reducing the maximal conductance of the Na+ current (GNa) by fixed 





Figure 2-8 – A schematic of the cell grid used in the 1D and 2D simulations.  An external stimulus was applied 
to cell 1 in 1D and cell (3,3) in 2D to initiate an AP.  
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Statistical Analysis   
 Patch-clamp data was obtained and analyzed using pClamp 8.0 (Axon Instruments, 
Union City, CA).  (GraphPad Software, Inc., San Diego, CA). Differences in recordings were 
determined by analysis of variance.  Differences between specific groups were seen using post-
hoc testing.  Data was presented as the mean ± SEM.  A p < 0.05 was considered statistically 





Control – 2 X 106 Cardiomyocytes 
5% ESC – 2 X 106 Cardiomyocytes and 1 X 105 mouse ESCs 
ESC CM – 2 X 106 Cardiomyocytes with diluted 1:1 media from ESCs for 24 hours and 
cardiomyocyte media   
IM –2 X 106 Cardiomyocytes with media kept overnight in an incubator 
 
3.1 ESC Exposure Alters Cardiac Electrophysiology 
Prolongation of FPD in Treatment Conditions 
 Cardiomyocytes that were exposed to ESCs for 96 h had a significantly longer FPD (44.0 
± 6.2 ms) as compared to the control (26.3± 2.2 ms, n=9) (Figure 3-1).  In the ESC CM group, 
the FPDs increased (46.0± 7.8 ms, n= 8), which is significantly higher than the controls.  The 5% 
ESC and ESC CM groups were not statistically different from each other.  To ensure that the 
effects of the CM were not a result of overnight incubation, incubated media (IM) only 
experiments were conducted.  The FPDs of IM were comparable to those of controls suggesting 
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that the results are due to the paracrine effect of ESCs.  
 
Prolongation of ISI in Treatment Conditions 
ISI showed a 164% increase in the 5% ESC group as compared to the control (Figure 3-
2). The ISI of the 5% ESC group was 947.8 ± 214.6 ms (n=7) and the ISI of the control group 
was 358.3 ± 62.9 ms. (n=10; p<0.05).  The ESC CM group showed a similar trend with an ISI of 
682.0 ± 128.5 ms (n=9).  ISI in the IM group was not statistically different from the control.    
 
 
Figure  3-1- Mean FPD at 96h.  Co-culture with ESCs prolongs cardiomyocyte FPD.  The mean FPD ± SEM are 
shown for the control, 5% ESC, ESC CM, and IM groups at 96h. *, p < 0.05 as compared to control.  
 37 
 
Reduction in Conduction Velocity 
 ESC exposure resulted in a 62% reduction in CV as compared to controls (Figure 3-3).  A 
similar reduction occurred upon exposure of cardiomyocytes to the CM.  The CV for the control 
was 14.23 ± 1.27 cm/sec.  The CV for the 5% ESC and ESC CM groups were 4.56 ± 1.29 cm/sec 
and 4.18 ± 0.40 cm/sec respectively.  Both 5% ESC and ESC CM groups were statistically 
different from the control group.  The IM group had values that were not significantly different 
from the control.   
 
Figure 3-2- Mean ISI at 96h.  Co-culture with ESCs prolongs cardiomyocyte ISI.  The mean ISI ± SEM are 
shown for the control, 5% ESC, ESC CM and IM groups at 96h. *, p < 0.05 as compared to control. 
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Figure 3-3- Mean CV at 96h.  Co-culture with ESCs tends to prolong CV in cardiomyocyte co-cultures. The 
mean CV ± SEM are shown for the control, 5% ESC, ESC CM and IM groups at each time point. *, p < 0.01 as 
compared to control cultures.   
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3.2 ESC-Mediated Reductions in Na
+
 and Cx43 Channels May Explain the Changes in 
Cardiomyocyte Behavior 
 ESC Co-Culture and Conditioned Media Conditions Reveal a Decrease in Connexin43 
Expression 
 No differences in total Cx43 expression were observed between treatments and controls 
(Figure 3-4 A).  A distinct difference in phosphorylation of Cx43 was seen in the treatments as 
compared to the controls (Figure 3-4 B).  Western blots suggest that changes in the 
phosphorylation state of Cx43 upon ESC exposure.  Phosphorylated Cx43 is represented by the 
upper P1 and P2 bands.  The unphosphorylated form is represented by the lower band or P0.   
Figure 3-4 C).  A statistically significant reduction in the Cx43 ratio was seen in the 5% ESC 
group as compared to the control group.  There were similar statistically significant reductions in 
phosphorylated Cx43 with ESCs CM.   
 
 
Figure 3-4- Cx43 expression.  (A) Total Cx43 expression as a percentage of the control.  (B) Western Blot for 
Cx43 expression. There was an  increase in un-phosphorylated Cx43 in treatments as compared to the control. 
(C) The ratio of phosphorylation (P1+P2)/un-phosphorylated (P0) Cx43 of  5% ESC and ESC CM as compared 




3.3  Cardiac Na
+ 
Channels are Downregulated in Treatment Conditions as Compared to 
Control 
 Cardiac Na+ channel expression was significantly decreased upon exposure to ESCs or 
CM (Figure 3-5 A).  Na+ channel expression was 64.9 ± 6.0% in the ESC group of the control 
(n=8) and 73.8 ± 13.8 % of the control (n=7) in the ESC CM group (Figure 3-5 B). Na+ channel 
expression was significantly reduced in both 5% ESC and ESC CM cultures.   
 Downregulation of the SCN5a gene transcription was seen in both the 5% ESC and ESC 
CM groups, using real time PCR (Figure 3-6).  The SCN5a mRNA abundance in the 5% ESC 
group was 19.8 ± 10.0% (n=3) of the control and 48.8 ± 10.3% (n=3) of the control in the ESC 
CM group. 
A concomitant downregulation of Na+ current was observed.  (Figure 3-7A).  There was a 
statistically significant decrease in the peak Na+ current from 47.7 ± 2.3 pA/pF (n=10) in the 
controls to 29.4± 1.7 pA/pF (n=10) in the ESC CM.  Peak conductance was reduced by 38% 
(Figure 3-7 B).  There were no statistically significant changes in steady state activation or 
inactivation, however. Therefore, exposure of cardiomyocytes to ESCs resulted in reductions in 







Figure 3-6 – RT-PCR of SCN5A. Reduction in Na+ channels in treatments as compared to Control (*, p<0.05)   
 
 
Figure 3-5 - Cardiac Na+ channel.  (A) Reduction in Na+  channels in treatments as compared to Control (*, 
p<0.01)  (B) Western Blot showing the decrease in Na+  channel expression in both 5% ESC and ESC CM 





Figure 3-7 – Na+ channel IV Curve (A) Average current voltage relationships for Na+ current for the control and 
ESC CM groups. (B) Peak whole-cell Na+ conductance 
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3.4 Modeling Suggests that the Molecular Changes Observed are Sufficient to Explain 
the CV Decrease  
The LR model of the mammalian ventricular action potential was used to investigate the 
effects of molecular changes in connexins and Na+ channels on CV.  A 2D model consisting of 
individual cells connected through resistive gap junctions was implemented.  A representative 
sequence of depolarization (red) and repolarization (blue) depicting intermediate membrane 
potentials of the myocytes using the simulation is illustrated in Figure 3-8.  APs were initiated by 
an external stimulus applied to the middle of the 2D grid.  Since uniform coupling was assumed, 
APs propagated uniformly in all directions (Figure 3-8). 
 
The effect of changes in connexin and Na+ channel expression seen in experiment were 
simulated by reducing gj and GNa by the fixed percentages shown in Figure 3-9.  The model 
predicted a 51% and a 41% decrease in CV for the 5% ESC and the ESC CM groups, 
 




respectively  MEA data showed a 67% and a 70% decrease in CV for the 5% ESC and the ESC 
CM groups respectively, and similar changes were observed in the model.  ISI and APD were not 
studied using the model.  Figure 3-9 is a summary of the findings from the simulation; it suggests 
that the reductions in Na+ current and connexin expression were sufficient to explain the majority 
of the reductions in CV in the treated cultures.  In the model, the Cx43 reductions were based on 
the changes in phosphorylation patterns seen in the western blot analysis.  It was assumed that P0 





Figure 3-10 – Effects of Na+ channel and connexin changes on CV.  Based on simulations, connexin changes 
have a larger effect on CV than Na+ channel. 
 
 
Figure 3-9 – Comparison of the experimental CV and simulation CV.  CV of the control in the model was taken 
as 15.5 cm/sec.   
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The simulations were conducted by incorporating the observed changes in connexin and Na+ 
channel expression in the model without including ESC cells.  Therefore, additional simulations 
were conducted in which the role of incorporating cells with “ESC like” properties randomly in 
the 2D grid mimicking in vitro conditions.  In order to achieve this, a random number generator 
algorithm was used to identify cells within the 2D grid that were subsequently converted to 
“ESC-like” cells.  Since very little information is available regarding the electrophysiological 
properties of ESCs, they were simulated by clamping the membrane potential of the randomly 
identified cells to -35 mV.  
The consequences of converting a fixed percentage of cells to ESC-like cells were also 
tested.  A representative sequence of events occurring after conversion of 0.25 % of all the cells 
(100 of 40,000) to ESC cells is shown in Figure 3-9.  Increasing the number of ESC-like cells (to 
200) decreased the probability of a successful AP propagation following an external stimulus.  
This was mainly due to interactions between the depolarized ESC-like cells and the normal 






Figure 3-11 – Simulation to investigate role of ESCs on the spontaneous depolarization of myocytes.   Each 
point corresponds to one cell with red being depolarized (>10 mV) and blue representing the resting potential 
(<-84mV). The top 3 panels show spontaneous depolarization. The bottom three panels show an AP initiated at 
the left column (after the initial spontaneous depolarization) propagating relatively uniformly from left to right.  




4.1 Review of Findings and Implications 
 
We have shown that ESCs have an effect on cardiomyocyte electrophysiological 
behavior. In our experiments, cardiomyocytes cultured with ESCs showed longer FPD (Figure 3-
1), increased ISI (Figure 3-2), and a reduced CV (Figure 3-3).  These changes correlated with 
reductions in phosphorylated Cx43 and Na+ channel expression. The finding that ESC CM had 
the same effect on electrophysiological properties as ESC co-cultures implies that the results 
seen are because of paracrine factors and not physical contact between ESCs and 
cardiomyocytes.60  
To better understand what was causing the changes, we examined the molecular 
determinants of CV further.  There are two major determinants of CV, Cx43, which is 
responsible for intercellular communication, and Na+ channels, which generate current for 
conduction.  Protein analysis revealed a decrease in phosphorylated Cx43 (Figure 3-4 C) and 
cardiac Na+ channel expression (Figure 3-5 A).  RT-PCR showed a corresponding reduction in 
SCN5A mRNA abundance in ESC CM treated cells but no changes in Cx43 mRNA, suggesting 
that paracrine factors caused transcriptional changes in Na+ channel expression and post-
transcriptional changes in Cx43 phosphorylation.  Assuming that dephosphorylated Cx43 did not 
participate in functionally active connexons, the simulations studies suggested that these changes 
were sufficient to explain the majority of the conduction slowing observed.  
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4.2 Cardiomyocyte Cx43 Phosphorylation is Altered by ESC Paracrine Factors 
Cx43 is a phosphoprotein, and changes in connexin phosphorylation have an affect on 
channel properties.61  Phosphorylation of Cx43 appears to play a key role in channel assembly 
and the determination of channel conductance properties.  Under normal conditions, almost all of 
Cx43 is found in the phosphorylated form.62  Cx43 dephoshorylation is caused by a response to 
chemical agents or pathophysiologic conditions like myocardial ischemia which promotes 
uncoupling.  Dephosphorylation Cx43 has been shown to reduce gap junction communication 80  
and subsequently CV reduction in myocytes.  Since there was no change in total Cx43, changes 
in phosphorylation patterns may be responsible for the observed changes in myocyte behavior.  
In ischemic hearts, immunoblot analysis showed that the total amount of Cx43 remained constant 
but showed an increase in desphysophorylated Cx43.63   
Cx43 phosphorylation is controlled by a balance of kinase and phopshatse activities. 
Cx43 is associated with phosphatses that can regulate activity.  Nevertheless, the lack of effect 
that we observed with okadaic acid, a phosphatase inhibitor suggests that the lack of 
phosphorylation observed is likely secondary to reduced kinase activity. Among those kinase 
known to phosphorylate Cx43 are mitogen-activated protein kinase (MAPK) or protein kinase C 
(PKC) has been associated with decreased gap junction intercellular communication.65  Studies 
have suggested that disruption in gap junction communications were due to activation of an 
phosphatidylinositol 3-kinase/Akt pathway.66    
  In addition, Doble et al.67 demonstrated that fibroblast growth factor 2 (FGF-2) led to 
the activation of PKC, which brought about changes in the phosphorylation state of Cx43.  They 
also showed that FGF-2 does not cause changes in Cx43 mRNA.67  Even though, FGF-2 induced 
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increases in phosphorylated Cx43 on a Threonine residue, this study suggests that there might be 
other factors that do not change Cx43 mRNA but affect phosphorylation patterns.      
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4.3 ESC Conditioned Media Induces Transcriptional Changes in SCN5A 
Based on the concordance of RT-PCR,Western blot, and current data, it appears that ES 
cell exposure results in transcriptional downregulation of the Na+ channel in cardiomyocytes.   
The promoter region of the channel has been characterized.  Based on agents known or thought 
to be secreted from stem cells, possible mediators include… 
For example, in cultured rat cardiac myocytes, adding Na+ channel blocker mexiletine 
increase Na+ channel mRNA expression and lead to an increased number of Na+ channels.68  
Conversely, the addition of Ca2+ ionophore A23187 caused increases in intracellular calcium, 
which in turn lead to a fivefold decrease in Na+ channel expression, while the addition of the 
calcium chelator BAPTA-AM had opposite results.69-71  
This effect is consistent with that of cytokinesknown to transcriptionally regulate 
expression of other ion channels proteins including calcium regulating proteins (SERCA2), 
calcium releasing channel (CRC) and L type Ca+2 channels through gene expression at the 
transcript level.72,73  
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4.4 Co-Culture of Other Cell Types with Cardiomyocytes Has Similar Paracrine Effects 
Others have seen effects of cells on native CMs. LaFromboise et al.74 demonstrated that 
co-culture of fibroblasts with cardiomyocytes resulted in changes in myocyte structure and 
functional characteristics. Hypertrophy, intracellular expression of vimentin, and reduction of 
chronotropic contractile activity were induced.  Research shows that hypertrophy leads to AP 
prolongation and increased ICa.
75  Myocytes cultured with CM from feeder-cells have also been 
shown to exhibit hypertrophy through the activation of different protein kinase pathways.76 In 
initial studies (data not shown), we saw similar effects in fibroblast-CM, implying that the effect 
of ESCs may not be unique.   Researchers  also saw increases in the levels of vascular 
endothelial growth factor (VEGF), growth-regulated α-protein (GRO/KC), monocyte 
chemoattractant protein-1 (MCP-1), leptin, macrophage inflammatory protein-1 α (MIP-1 α), IL-
6, IL-10, IL-12p70, and IL-17, and tumor necrosis factor (TNF)- α in their fibroblast conditioned 
media.74  If our cells have a similar secretory profile, then there are several possible candidates to 
mediate the paracrine effects.  For example, VEGF has been shown to cause Cx43 remodeling, 
which leads to disruptions in gap junction intracellular communication (GJIC). Studies have also 
shown that TNF- α  causes downregulation of Cx43.77 The effects of the other factors on the 
electrophysiological properties of cardiomyocytes still need to be further investigated. 
Using optical mapping, Chang et al.78 demonstrated that CV was reduced in co-cultures 
of MSCs and cardiomyocytes as compared to controls.  The effects were dose dependent. 
Reentrant arrhythmias were induced in 86% of co-cultures containing 10% and 20% but not in 
controls or co-cultures containing only 1% MSCs.78  We also observed no significant 
electrophysiological changes in co-culture studies with 1% ESCs as compared to controls, 
suggesting similarities between our studies and implying the effect on conduction velocity may 
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not be unique to one type of stem cell..  The MSC studies also demonstrated that co-cultures 
exhibiting decreased CV are predisposed to reentrant arrhythmias.  Their study suggested that 
reduced CV was due coupling of cardiomyocytes with unexcitable MSCs.78  This is different 
from our study in the flowing ways as our ESC CM experiments suggested that without 
unexcitable ESCs in our culture, there were similar reductions in CV.  MSCs are known to 
secrete growth factors and cytokines including macrophage, granulocyte, and granulocyte-
macrophage colony stimulating factors, stem cell factor 1, leukemia inhibitory factor, stromal 
cell–derived factor-1, Flt-3 ligand, and IL-1, -6, -7, -8, -11, -14, and -15.79  The authors speculate 
that the proarrhythmic risk of MSCs were due to these secreted factors.78   Since ESCs are also 
unexcitable and our experiments suggest that paracrine factors are responsible for the altered 
myocyte behavior, it is possible that ESCs secrete similar growth factors that cause 
proarrhythmic behavior.     
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4.5 Relevance of LR Model for APs 
Modeling suggested that the observed Na+ channel and Cx43 changes were sufficient to 
explain the reduced CV.  Based on the simulation, it appears that both Cx43 and Na+ channel are 
equally responsible for the reduced CV (Figure 3-10).     
A possible limitation of the AP model used was that it did not take into account the 
presence of the stem cells.  Nevertheless, the statistically indistinguishable effect of CM and the 
similar findings with Na+ channels and CXs suggests that the cells that introduction of a small 
number of inexcitable cells is not likely to change the model conclusions dramatically.  In 
addition, due to modeling constraints, the model uses only about 400 cells whereas our cultures 
have over 2 million cells.  Since uniform conduction is presumed, it is possible to assume that 
the simulation is a small subset of the whole culture.  Slight discrepancies between the 
experimental result and the model may have resulted because the model is based on a adult 
porcine channel parameters, while our cardiomyocytes are from neonatal rats..   
    
Also, certain simplifying assumptions were made to make the modeling more tractable. 
Connexins were modeled as simple resistors and changes in Cx expression was modeled by 
changing resistance (Rg).   The Na+ channel changes were modeled by reducing the maximal 
conductance of the Na+ current (GNa) by fixed percentages.  Finally, the data and modeling do 
not speak to the origin of the changes in ISI or FP duration. 
 
Deleted: With the reductions in CV 
seen in our cultures, it was important to 
determine if the results we saw were 
based on the changes in Cx43 and Na+ 
channel alone or if there were other 
factors responsible for causing such a 
reduction
Deleted: We used an established model 
for APs to further investigate the effects 
of the reduced expression of both 
connexins and cardiac Na+ channels on 
CV.  The LR Model was chosen because 
it correctly simulates the interaction of 
excitation and repolarization,56 which is 
important because reentrant arrhythmias 
have this type of interaction between the 
head and tail of the reentrant AP.80  The 
results of the simulation suggest that 
changes in Cx43 and Na+ channel 
drastically alter the myocyte behavior.  
Deleted: The simulation and 
experimental results are not equivalent 
but they are comparable.  While there 
may be some other factors that affect CV, 
this simulation helped identify the major 
factors.   
Deleted: in this study is that uniform 
conduction throughout the culture is 
assumed, which may not always be the 
case.  Also, the model has a single 
activation site, which is not always the 
case as some cultures have multiple 
activation sites.  These limitations, 
however, minimally affect our results.  
Deleted: The 
Deleted: model
Deleted: model is a rodent one
Deleted: Also, in this study neonatal 
cells were used, which have higher 
beating rates than adult cells. These 
assumptions are reasonable, since the 
purpose of this study was to see if the 
results of our experiments were plausible 
and not to determine exact values.
Deleted: Even though the results 
obtained with the model are not exactly 
the same as seen in our MEA data, 
similar trends were observed.  The 
limitations previously mentioned may 
partially explain the discrepancy.  While 
Cx43 and Na+ current are major 
determinants of CV, there are other 
factors that affect conduction, like 
calcium concentration, that have not been 
considered in the model.   
Deleted: In this model,
Deleted: c
Deleted: simply 
Deleted:  This is a simplified method of 
simulating changes in Cx and Na+ 
channel expression.  In the LR model, 
however, that is how Na+ channel and Cx ... [1]
 54 
4.6 Limitations, Future Directions and Conclusions 
This study showed that the introduction of ESCs leads to alterations in cardiomyocytes 
that could be arrhythmogenic, but did not demonstrate arrhythmia formation directly.  The study 
did however show that addition of ESCs in vitro cause cardiomyocytes to display pro-arrhythmic 
phenotype with longer APDs and reduced CV.  Future experiments using an in vivo model will 
be required to demonstrate arrhythmia development in response to ESC transplantation.  Our 
data do not speak to the effect of ESC-derived CMs on native heart cells or of CMs on ESC 
differentiation.  These needs to be further investigated.  Also, these were relatively short term 
experiments.  Since the goal of in vivo cell transplantation is to have long term engraftment, the 
long term effects on cardiomyocytes may differ. Moreover, our studies do not take into account 
the effects of altered immune response as part of cell replacement.  
Results may differ by species. Our studies look at the effect of mouse ES cells on rat 
CMs.  Future studies will need to look at a same species model.     
Finally, although Cx43 is the most widely available gap junction protein found in 
ventricular cells, there are trace amounts of Cx40.  Studies have shown increased amounts of 
Cx40 is found in failing ventricular heart tissue.82  Increasing the ratio of Cx40 to Cx43 has been 
shown to reduce propagation velocity 83 and there is speculation that the Cx40 might have an 
effect on working ventricular myocyte junctions.84  Future studies may need to look at the effect 
of Cx40 on propagation velocity.   
In conclusion, ESCs hold promise as a cellular therapy option because of their potency 
and renewability.  At the same time, ESCs demonstrate arrhythmic potential and before ESCs 
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can be used as a cell source, their interaction with the native myocardium should be further 






PROCEDURE OF NEONATAL CARDIOMYOCYTE ISOLATION 
 
Day 1: Perform on ice. 
1. The beating hearts from 1- to 2-day-old Sprague-Dawley rats were surgically removed 
under anesthesia, and immediately place the heart in the centrifuge tube, which contained 
35 ml sterile calcium- and magnesium-free Hank’s Balanced Salt Solution (pH7.4), to 
chill and rinse. Swirl the tube to rinse hearts, and then pour off most of liquid. Rinse the 
hearts with 10 ml of calcium- and magnesium-free Hank’s Balances Salt Solution, pour 
off the liquid as before, and then transfer the hearts to the Petri dish.  Remove the atrium 
and mince the tissue of ventricles with small scissors to less than 1 mm3, pieces keeping 
tissue at 0 ºC. 
2. Add calcium- and magnesium-free Hank’s Balanced Salt Solution to Petri dish to a final 
volume of approximately 9 ml. 
3. Transfer 1 ml of the contents of the trypsin into the Petri dish and mix completely by 
swirling. Final trypsin concentration is 50 µg/ml. 
4. Place the lid on the Petri dish and immediately place in refrigerator overnight (16-20 
hours) at 2-8 ºC. 
Day 2 
1. Remove Petri dish from refrigerator and bring to tissue culture hood on ice. Transfer 
tissue to 50 ml centrifuge tube on ice using wide-mouth pipette. 
2. Transfer 2000 µg Trypsin Inhibitor in 1 ml calcium- and magnesium-free Hank’s 
Balanced Salt Solution into tube and mix. 
3. Oxygenate tissue for 1 min by passing oxygen over the surface of the liquid. 
4. Warm tissue in water bath at 37 ºC for 30 min. 
5. Slowly transfer 1500 Units of Collagenase in 5 ml Leibovitz L-15 Media into tube 
and mix. Cap tube tightly. 
6. Place tube on slowly rotating instrument (Techne Hybridizer HB-1D) at 37 ºC and 
incubate for 45 min. 
7. Remove tube from incubator and return to tissue culture hood. Triturate about 10 
times to release cells with standard 10 ml plastic serologic pipette. 
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8. Rinse a Cell Strainer (BD Falcon, REF 352350) with 1 ml of the L-15 culture 
medium. Allow tissue residue to settle 4 min, then (with same pipette) filter the 
supernatant through the Cell Strainer into a fresh 50 ml centrifuge tube. 
9. Add 5 ml additional L-15 culture medium to tissue residue, repeat trituration step. 
Allow tissue residue to settle as before, then filter cells through the same Cell 
Strainer. Rinse mesh gently with 2 ml L-15 culture medium, oxygenate cells 1 min, 
then allow filtered cells to remain undisturbed about 20 min at room temperature.  
10. Swirl cells gently, and remain undisturbed 10 min at room temperature. Sediment 
cells at 1000rpm for 3 min.  
11. Suspend final cell pellet in Dulbecco’s Modified Eagle Medium (DMEM) with 10% 
fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin (Invitrogen 
Corp. Carlsbad, CA). Pipette gently to disperse. Count the cells using a 
hemacytometer, and estimate cell viability by using Trypan Blue exclusion 
procedures, then pre-plate cells in 150 mm tissue culture dish. Place dishes in a 37 ºC 
incubator for 90 min in order to reduce the contamination of cardiac fibroblast. 
12. Take out the dishes from the incubator, transfer the unattached cells into a 50 ml 
centrifuge tube. Sediment cells at 1000rpm for 3 min, suspend cell pellet in DMEM 
with 10% FBS, count alive cell number.  
13. Plate myocytes on the multi-electrode arrays (MEA) (pre-coated with 0.1 % Gelatin) 
at a density of 2×106, and on T-25 flasks. 
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 This is a simplified method of simulating changes in Cx and Na+ channel 
expression.  In the LR model, however, that is how Na+ channel and Cx expression are 
modeled.  These interactions, in vivo, are likely to be more complex than in our model. 
 This simplification could explain the slight variation seen between the model and the 
experimental results.  
 
 
